Information Provided By:
Fly News Breaks for July 27, 2018
CHRS
Jul 27, 2018 | 09:27 EDT
The European Medicines Agency this morning provided a positive opinion on Coherus Biosciences' version of Neulasta, Citi analyst Mohit Bansal tells investors in a research note. This is positive news as it "significantly lowers" regulatory risk for Neulasta in the U.S. as well, Bansal tells investors in a research note. He notes that while the applicant name is not Coherus on the two applications receiving positive opinions today, the drug name trademark "Udenyca" is registered under Coherus and it seems a third party filed the application on Coherus' behalf. The analyst sees the stock trading in the $21-$25 range on the news. He keeps a Buy rating on Coherus Biosciences with a $25 price target. The stock in premarket trading is up 8%, or $1.40, to $19.75.
News For CHRS From the Last 2 Days
There are no results for your query CHRS